06.30.11
Daily consumption of Bifidobacterium lactis HN019 (also known as HOWARU Bifido and DR10) decreases colonic transit time (CTT) and improves functional gastrointestinal symptoms in otherwise healthy adults, according to a collaborative study by Danisco and Fonterra Co-operative Group. Results were published in the Scandinavian Journal of Gastroenterology.
The double-blind, randomized, placebo-controlled clinical trial enrolled 100 patients, aged 25 to 65 years old with mild gastrointestinal symptoms. The subjects were randomized to ingest B. lactis HN019 at daily doses of 1010 CFU (High; n=33), 109 CFU (Low; n=33), or placebo (n=34) for 14 days. CTT was assessed by X-ray on days zero and 14 following six days of ingestion of capsules containing radio-opaque markers. Frequency of upper gastrointestinal symptoms (such as nausea, vomiting, regurgitation, abdominal pain and gurgling) and lower gastrointestinal symptoms (such as flatulence, constipation, diarrhea and irregular bowel movements) were recorded before and after supplementation using a Likert scale.
The average CTT decreased in the high (28 hour reduction) and low (19 hour reduction) groups, but not with the placebo group. Of the nine gastrointestinal symptoms investigated, the high group improved in eight, the low group improved in seven and the placebo group improved in only two symptoms. Food consumption habits were similar among the three groups over the 14-day study period.
Researchers concluded that daily B. lactis HN019 supplementation is well-tolerated, decreases CTT according to the dose taken and improves functional gastrointestinal symptoms in otherwise healthy adults. No adverse events were reported in any group. For further information: www.danisco.com; www.fonterra.com
The double-blind, randomized, placebo-controlled clinical trial enrolled 100 patients, aged 25 to 65 years old with mild gastrointestinal symptoms. The subjects were randomized to ingest B. lactis HN019 at daily doses of 1010 CFU (High; n=33), 109 CFU (Low; n=33), or placebo (n=34) for 14 days. CTT was assessed by X-ray on days zero and 14 following six days of ingestion of capsules containing radio-opaque markers. Frequency of upper gastrointestinal symptoms (such as nausea, vomiting, regurgitation, abdominal pain and gurgling) and lower gastrointestinal symptoms (such as flatulence, constipation, diarrhea and irregular bowel movements) were recorded before and after supplementation using a Likert scale.
The average CTT decreased in the high (28 hour reduction) and low (19 hour reduction) groups, but not with the placebo group. Of the nine gastrointestinal symptoms investigated, the high group improved in eight, the low group improved in seven and the placebo group improved in only two symptoms. Food consumption habits were similar among the three groups over the 14-day study period.
Researchers concluded that daily B. lactis HN019 supplementation is well-tolerated, decreases CTT according to the dose taken and improves functional gastrointestinal symptoms in otherwise healthy adults. No adverse events were reported in any group. For further information: www.danisco.com; www.fonterra.com
